HCPCS G9284: NSCLC Biopsy/Cytology Report Without Specific Histologic Classification

HCPCS Level II code G9284 denotes pathology and cytology reports for non–small cell lung cancer (NSCLC) in which the specimen is not classified into a specific histologic subtype or is documented as NSCLC-not otherwise specified (nsclc-nos) with an explanation. Clear histologic classification influences therapeutic selection, clinical trial eligibility, and downstream molecular testing, making documentation quality an important national concern for oncology care quality and care coordination. Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will find a concise briefing on the clinical and administrative implications of G9284, including what the code represents, typical sites of service, and how it relates to pathology reporting standards. The publication summarizes common billing modifiers associated with specimen and service reporting, notes the absence of specific ICD-10 or taxonomy details when not provided, and outlines areas where documentation may affect coding and claims processing. The piece highlights benchmarks and policy-relevant considerations for payers and provider organizations without offering clinical recommendations. Data not available in the input is noted where applicable.

Billing Code Overview

HCPCS Level II code G9284 describes documentation where a biopsy and cytology specimen report for non-small cell lung cancer (NSCLC) does not specify a more precise histologic subtype or is reported as NSCLC, not otherwise specified (nsclc-nos) with an accompanying explanation. This code pertains to the pathology/cytology reporting of lung cancer specimens and captures documentation quality related to histologic classification.

Service type: Pathology / Cytology specimen reporting for lung cancer diagnosis

Typical site of service: Hospital pathology laboratories, independent pathology labs, or outpatient surgical centers where biopsy and cytology specimens are processed and reported.

Clinical Context

A 67-year-old current/former smoker presents with progressive cough, hemoptysis, and an enlarging pulmonary mass on chest CT. Bronchoscopy with transbronchial biopsy or CT-guided percutaneous core needle biopsy is performed to obtain tissue for histopathology and ancillary studies. The pathology report documents malignant non–small cell carcinoma but does not classify the tumor into a specific histologic subtype (for example, adenocarcinoma, squamous cell carcinoma) nor provides an explanation for classifying as NSCLC-NOS. The specimen may be limited in quantity, have crushing artifact, or lack immunohistochemical and molecular testing due to insufficient material, precluding definitive subclassification. Typical site of service is an outpatient hospital or ambulatory surgery center for the biopsy procedure, and the pathology interpretation occurs in the hospital pathology laboratory or an independent pathology practice. Common clinical workflow includes radiology or pulmonology performing the biopsy, specimen submission to surgical pathology/cytology, preliminary cytology review for adequacy, and final pathology/cytology reporting noting NSCLC-NOS without further subclassification when diagnostic limitations exist.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services

Taxonomy Code	Specialty	Notes
`207RP0500X`	Pulmonary Disease	Pulmonologists commonly perform bronchoscopic biopsies and coordinate tissue acquisition.
`208800000X`	Diagnostic Radiology	Interventional radiologists frequently perform CT-guided percutaneous lung biopsies.
`207K00000X`	Thoracic Surgery	Thoracic surgeons perform surgical biopsies (VATS wedge resection) when minimally invasive tissue is required.
`207L00000X`	Pathology	Anatomic/clinical pathologists perform histologic and cytologic interpretation, and report `NSCLC-NOS` when subclassification is not possible.
`207C00000X`	Hematology-Oncology	Medical oncologists interpret pathology for treatment planning and may request additional testing.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C34.90`	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Primary diagnosis commonly associated with lung mass biopsies leading to pathologic diagnosis of NSCLC; used when location is not specified.
`C34.91`	Malignant neoplasm of right bronchus or lung	Used when the right lung is the lesion site requiring biopsy and pathology reporting.
`C34.92`	Malignant neoplasm of left bronchus or lung	Used when the left lung is the lesion site requiring biopsy and pathology reporting.
`R91.8`	Other nonspecific abnormal findings of lung field	Used for incidental imaging findings prompting biopsy to rule out malignancy when final pathology reports `NSCLC-NOS`.
`R04.2`	Hemoptysis	Symptom prompting diagnostic evaluation and biopsy in suspected lung cancer cases.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`31622`	Bronchoscopy, with transbronchial lung biopsy, single lobe	Performed by pulmonology to obtain tissue when central lesions are accessible; often precedes pathology reporting of `NSCLC-NOS`.
`32405`	Biopsy, lung or pleura, percutaneous needle; with imaging guidance	Percutaneous core needle biopsy performed by interventional radiology to obtain tissue for histology and cytology.
`32607`	Thoracoscopy, surgical; with lung biopsy (single lobe)	Video-assisted thoracoscopic surgical (VATS) biopsy providing larger specimens when percutaneous or bronchoscopic samples are insufficient for subclassification.
`88305`	Level IV surgical pathology, gross and microscopic exam	Common pathology code for biopsy specimens processed with routine histology and microscopy; may accompany a report that documents `NSCLC-NOS`.
`88172`	Cytopathology, immediate cytologic evaluation for adequacy (ROSE)	Rapid on-site evaluation during biopsy to assess specimen adequacy; limited or absent ROSE can contribute to `NSCLC-NOS` classification.

OpenPayer

Summary & Overview